biostudies-literatureDiouf IRocheNational Health and Medical Research Council1014-1024https://www.ebi.ac.uk/biostudies/studies/S-EPMC10946605biostudies-literatureUnknown30(4)<h4>Background and purpose</h4>This study assessed the effect of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS).<h4>Methods</h4>We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow-up ≥ 1 year, and Expanded Disability Status Scale (EDSS) score ≥ 3, with ≥1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12-month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics.<h4>Results</h4>Among 24,344 patients with relapsing MS, those on DMTs experiencedEuropean journal of neurologyVariability of the response to immunotherapy among subgroups of patients with multiple sclerosis.PMC10946605108051811291891140766Alroughani RSlee MKalincik TDeri NHamdy SKhurana DKarabudak RSola PVucic SYamout BShaygannejad VHughes SMaimone Dvan der Walt ALugaresi AVan Wijmeersch BAl-Asmi AMcCombe PVan Hijfte LHavrdova EKOzakbas SSinnige LGFIuliano Gde Gans KBuzzard KFerraro DSa MJMcGuigan CKappos LMacdonell RDuquette PSolaro CGrammond PTrevino-Frenk IPrat ADiouf ITurkoglu RBoz Cvan Pesch VShaw CHorakova DCsepany TCristiano EPerez Sempere ASchepel JBlanco YBergamaschi RPatti FCartechini EGouider RGerlach OLechner-Scott JRoos IAguera-Morales ELaureys GAltintas ARamo-Tello COnofrj MBarnett MSpitaleri DIzquierdo GEichau SGirard MAl-Harbi TMalpas CBGrand'Maison FButler ESkibina OPrevost JCastillo-Trivino TGray OGranella FButzkueven HSoysal ATerzi MPetersen TSanchez-Menoyo JLFragoso YHodgkinson SAmpapa RMoore FSharmin SfalseVariability of the response to immunotherapy among subgroups of patients with multiple sclerosis.<h4>Background and purpose</h4>This study assessed the effect of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS).<h4>Methods</h4>We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow-up ≥ 1 year, and Expanded Disability Status Scale (EDSS) score ≥ 3, with ≥1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12-month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics.<h4>Results</h4>Among 24,344 patients with relapsing MS, those on DMTs experienced2023-01-01T00:00:00Z2023 Apr2025-04-20T02:49:06.144Z2025-02-19T03:09:22.165ZS-EPMC109466053669289510.1111/ene.15706